CanSinoBIO vaccine production line in Tianjin Photo: Hu Yuwei/GT

CanSinoBIO's COVID-19 vaccine can provide a decent level of protection against the Omicron variant, the Chinese vaccine company said, and the company can quickly produce vaccines targeting mutations if a new variant that can evade immune resistance built by current vaccines emerges. 

CanSinoBIO told the Global Times on Tuesday that after one dose of the recombinant adenovirus vector COVID-19 vaccine (inhaled version) is given as a booster after two doses of inactivated vaccine in a trial, the pseudovirus neutralizing antibodies against Omicron will only have a slight decrease compared with the original strain of the coronavirus, which means that the vaccine's effectiveness in face of Omicron is just slightly lower than of the original type of the coronavirus. 

The levels of neutralizing antibodies against Omicron with a recombinant adenovirus vector dose as a booster after two inactivated ones are 10 times higher than those achieved when taking three doses of an inactivated vaccine, CanSinoBIO stressed.

"The company is developing a new vaccine targeting the Omicron variant. Once a new variant that can evade the immunity established through current vaccines emerges, we can quickly make vaccines against the new mutations," said CanSinoBIO.

China's top respiratory diseases expert Zhong Nanshan stressed the importance of booster shots at the Greater Bay Science Forum 2021 in Guangzhou, South China's Guangdong Province on Saturday

Experiments show that neutralizing antibodies can increase 200 times if people take CanSinoBIO's recombinant adenovirus vector COVID-19 vaccine as a booster after completing two inactivated vaccine shots for three to six months, said Zhong.

China had reported two Omicron cases as of Tuesday. One was detected among international arrivals in the northern port city of Tianjin, and the other was detected in the southern city of Guangzhou. The person who tested positive in Guangzhou returned to China from a foreign country in November. 

CanSinoBIO said that Tianjin and Guangzhou, as port cities, shoulder the responsibility of preventing imported cases, and if the company's inhaled vaccine could be granted emergency use, it will strive to produce the vaccine.

CanSinoBIO vaccine production line in Tianjin Photo: Hu Yuwei/GT

CanSinoBIO's COVID-19 vaccine can provide a decent level of protection against the Omicron variant, the Chinese vaccine company said, and the company can quickly produce vaccines targeting mutations if a new variant that can evade immune resistance built by current vaccines emerges. 

CanSinoBIO told the Global Times on Tuesday that after one dose of the recombinant adenovirus vector COVID-19 vaccine (inhaled version) is given as a booster after two doses of inactivated vaccine in a trial, the pseudovirus neutralizing antibodies against Omicron will only have a slight decrease compared with the original strain of the coronavirus, which means that the vaccine's effectiveness in the face of Omicron is just slightly lower than of the original type of the coronavirus. 

The levels of neutralizing antibodies against Omicron with a recombinant adenovirus vector dose as a booster after two inactivated ones are 10 times higher than those achieved when taking three doses of an inactivated vaccine, CanSinoBIO stressed.

"The company is developing a new vaccine targeting the Omicron variant. Once a new variant that can evade the immunity established through current vaccines emerges, we can quickly make vaccines against the new mutations," said CanSinoBIO.

China's top respiratory diseases expert Zhong Nanshan stressed the importance of booster shots at the Greater Bay Science Forum 2021 in Guangzhou, South China's Guangdong Province on Saturday

Experiments show that neutralizing antibodies can increase 200 times if people take CanSinoBIO's recombinant adenovirus vector COVID-19 vaccine as a booster after completing two inactivated vaccine shots for three to six months, said Zhong.

China had reported two Omicron cases as of Tuesday. One was detected among international arrivals in the northern port city of Tianjin, and the other was detected in the southern city of Guangzhou. The person who tested positive in Guangzhou returned to China from a foreign country in November. 

CanSinoBIO said that Tianjin and Guangzhou, as port cities, shoulder the responsibility of preventing imported cases, and if the company's inhaled vaccine could be granted emergency use, it will strive to produce the vaccine.